Xeris Pharmaceuticals Inc Stock News

Xeris recently reported encouraging Q1 earnings. The company's commercial products are off to a strong start, including their recently launched product, Recorlev. Xeris reaffirmed its full-year net pr

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO

Xeris Biopharma Holdings (NASDAQ: XERS ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 These 4 analysts have an average price target of $6.35 versus the current price of Xeris Biopharma Holdings at $2.815, implying upside. Below is a summary of how these 4 analysts rated Xeris Biopharma Holdings over the past 3 months. The greater the number of bullish ratings, the more positive analysts … Full story available on Benzinga.com

Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q4 2021 Results - Earnings Call Transcript

Xeris Biopharma Holdings (NASDAQ: XERS ) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Xeris Biopharma Holdings missed estimated earnings by 75.0%, reporting an EPS of $-0.42 … Full story available on Benzinga.com

Xeris Pharmaceuticals press release (XERS): Q4 GAAP EPS of -$0.42 misses by $0.14.Net Product Revenue of $21.36M (+201.3% Y/Y).Cash, cash equivalents, and short-term investments…

Companies Reporting Before The Bell • Despegar.com (NYSE: DESP ) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares UltraShort Russell2000 (NYSE: TWM ) is expected to report earnings for its fourth quarter. • Vivid Seats (NASDAQ: SEAT ) is projected to report quarterly loss at $0.07 per share on revenue of $139.54 million. • LumiraDx (NASDAQ: LMDX ) is expected to report quarterly loss at $0.09 per share on revenue of $69.60 million. • Life Time Group Hldgs (NYSE: LTH ) is expected to report quarterly loss at $0.41 per share on revenue of $356.92 million. • ATRenew (NYSE: RERE ) is likely to report quarterly loss at $0.03 per share on revenue of $368.91 million. • FuelCell Energy (NASDAQ: FCEL ) is estimated to report quarterly loss at $0.05 per share on revenue of $26.73 million. • Zealand Pharma (NASDAQ: ZEAL ) is expected to report quarterly loss at $0.93 per share on revenue of $11.98 million. • Yatsen Holding (NYSE: YSG ) is projected to report quarterly loss at $0.

Xeris Pharmaceuticals (NASDAQ:XERS) is scheduled to announce Q4 earnings results on Thursday, March 10th, before market open.The consensus EPS Estimate is -$0.16 (compared to -$11 a…

In the last trading session, 1.38 million shares of the Xeris Biopharma Holdings Inc. (NASDAQ:XERS) were traded, and its beta was 1.71. Most recently the company’s share price was $2.37, and it changed around $0.09 or 3.95% from the last close, which brings the market valuation of the company to $324.33M. XERS currently trades at … Xeris Biopharma Holdings Inc. (NASDAQ: XERS) Shares Might Go Down -48.59% This Year Read More »

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Thursday, March 10, 2022. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss t

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xeris recently updated on full-year 2021 sales, reporting that it had hit the upper end of guidance for Gvoke and Keveyis.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00pm Eastern Time. A live webcast of the fireside chat will be available o